564 U.S. 552 (2011)
In 2007 Vermont enacted the Prescription Confidentiality Law, also known as Act 80, whose central provision appears at Vt. Stat. Ann., Tit. 18, §4631(d).1 The statute prohibits pharmacies, health insurers, electronic transmission intermediaries, and similar entities from selling, licensing, or exchanging prescriber-identifying information, and from permitting its use for marketing prescription drugs, unless the prescriber consents.2 It likewise bars pharmaceutical manufacturers and marketers from using such information for marketing absent consent.3 The prohibitions are subject to enumerated exceptions that permit dissemination and use for health-care research, enforcement of insurance formularies, patient care-management communications, law enforcement, and purposes otherwise provided by law.4
Pharmaceutical manufacturers promote brand-name drugs through a process called detailing, in which sales representatives visit physicians' offices to present information and samples.5 Pharmacies receive prescriber-identifying information when filling prescriptions pursuant to federal and state requirements and routinely sell that information to data-mining firms.6 The data miners analyze the records, produce reports on individual physicians' prescribing patterns, and lease the reports to pharmaceutical manufacturers under nondisclosure agreements so that detailers can tailor their presentations.7
Respondents are three Vermont data-mining companies and the Pharmaceutical Research and Manufacturers of America, an association of brand-name drug manufacturers.8 They filed two consolidated actions in the United States District Court for the District of Vermont.9 The suits named the Vermont Attorney General and other state officials as defendants.10 Respondents sought declaratory and injunctive relief on the ground that §4631(d) violates their First Amendment rights.11
After a bench trial the district court denied relief.12 The Court of Appeals for the Second Circuit reversed, holding that the statute unconstitutionally burdens protected speech.13 The Supreme Court granted certiorari to resolve the conflict with decisions of the First Circuit upholding similar statutes in Maine and New Hampshire.14
The Vermont Legislature accompanied the statute with formal findings.15 Detailing often conflicts with state public-health goals.16 Use of prescriber-identifying data increases the effectiveness of brand-name marketing.17 The resulting increase in prescriptions of newer, more expensive drugs raises healthcare costs.18 The Act also funded an evidence-based prescription-drug education program intended to promote therapeutic and cost-effective prescribing.19
Whether Vermont's Prescription Confidentiality Law imposes content- and speaker-based burdens on protected expression that subject the statute to heightened judicial scrutiny?20
The First Amendment requires heightened scrutiny whenever the government creates a regulation of speech because of disagreement with the message it conveys.21 Content-based restrictions on speech are presumptively invalid, and speaker-based restrictions that target particular speakers for disfavored treatment likewise trigger heightened review.22 Commercial speech receives protection under the same principles, and a law that disfavors speech with a particular content or from particular speakers must satisfy rigorous scrutiny even if characterized as commercial regulation.23
Yes. Vermont's Prescription Confidentiality Law, enacted in 2007 as Act 80 and codified at Vt. Stat. Ann., Tit.
18, §4631(d), prohibits pharmacies and similar entities from selling or disclosing prescriber-identifying information for marketing purposes and bars pharmaceutical manufacturers from using that information for marketing absent prescriber consent, while permitting the same information to be sold, disclosed, and used for health-care research, formulary enforcement, patient communications, law enforcement, and other listed purposes.24 The statute therefore draws distinctions based on the content of the purchaser's or user's speech.25 It also applies its prohibitions only to pharmaceutical manufacturers, marketers, and the data miners who supply them, while leaving other speakers such as insurers, researchers, and the State itself free to obtain and use the identical information.26 These content- and speaker-based burdens on protected expression, confirmed by the legislature's formal findings that detailing conflicts with state goals and that prescriber data increases the effectiveness of brand-name marketing, require the application of heightened judicial scrutiny.27
Vermont's Prescription Confidentiality Law imposes content- and speaker-based burdens on protected expression and is therefore subject to heightened judicial scrutiny.28
Related opinions on this issue
Justice Thomas joined the Court's opinion but wrote separately to underscore that the Vermont statute constitutes a content-based restriction on speech.29 He stressed that such a restriction cannot survive even the intermediate level of scrutiny that applies to commercial speech.30 In Thomas's view, the interests asserted by the State in physician privacy and related concerns fall short of justifying the burden the law places on protected expression.31
Joined by Justices Ginsburg And Kagan
Justice Breyer dissented.32 He contended that the statute should not be subjected to heightened First Amendment scrutiny at all.33 The law regulates the sale and use of information collected pursuant to a traditional regulatory program rather than speech in the conventional sense.34
He argued that ordinary economic regulation affecting commercial messages incidentally should be reviewed under the more lenient standards appropriate for commercial or regulatory legislation.35 Heightened scrutiny would improperly shift policy judgments from legislatures to courts.36
Whether Vermont's asserted interests in protecting physician privacy, the integrity of the doctor-patient relationship, public health, and reducing healthcare costs justify the law's restrictions under heightened scrutiny?37
To survive heightened scrutiny, a content- and speaker-based restriction on protected speech must directly advance a substantial governmental interest and be drawn to achieve that interest without burdening substantially more speech than necessary.38 Even under the intermediate scrutiny framework for commercial speech, the State must demonstrate a reasonable fit between its ends and the means chosen, and fear that truthful information will persuade listeners provides no lawful basis for restricting speech.39
No. Although Vermont's interests in physician privacy, the doctor-patient relationship, public health, and controlling healthcare costs are substantial, the Prescription Confidentiality Law does not directly advance those interests in a permissible manner.40 The statute permits widespread dissemination and use of prescriber-identifying information for numerous non-marketing purposes, undermining any claim that it meaningfully protects confidentiality.41 The legislative findings acknowledge that the law's purpose is to diminish the effectiveness of brand-name detailing by restricting only those speakers.42 The State could have pursued its goals through less restrictive means such as an opt-in consent requirement or direct counter-detailing, yet instead chose to burden disfavored speech by disfavored speakers.43
The law rests on the premise that truthful marketing information may lead physicians to make undesirable prescription decisions.44 It therefore fails the requirement that restrictions on speech be justified by something more than a difference of opinion about the value of the message.45
Vermont's asserted interests do not justify the Prescription Confidentiality Law's restrictions under heightened scrutiny.46
Related opinions on this issue
Joined by Justices Ginsburg And Kagan
Justice Breyer maintained that even under Central Hudson intermediate scrutiny the statute satisfies constitutional requirements because it directly advances substantial state interests in public health, privacy, and cost containment through a reasonable fit that does not burden more speech than necessary.47 He noted that the record supports the legislature's judgment that restricting the use of prescriber data for marketing promotes unbiased information and lowers costs.48 He argued that ordinary economic regulation affecting commercial messages incidentally should be reviewed under the more lenient standards appropriate for commercial or regulatory legislation.
Justice Thomas agreed with the majority that the State's interests fail to justify the law even under commercial-speech scrutiny.49 He reiterated that the content-based restriction cannot be sustained because the asserted privacy and public-health rationales do not directly advance the goals without imposing an unjustified burden on protected expression.50 Thomas emphasized that the statute's speaker- and content-based burdens require rigorous review regardless of how the State characterizes its regulatory aims.51
The law's selective application to pharmaceutical manufacturers and data miners reveals an impermissible effort to suppress disfavored commercial messages.52